Drug Development Drug Pricing Immunization 
STAT
JANUARY 17, 2025
Today, we see insulin-producing cells survive in a human body without triggering an immune rejection, and have some big news from CMS. Hope those of you who were in San Francisco for J.P. Morgan are resting, recovering, and not coping with any quad-emic strains. Read the rest…
STAT
MARCH 28, 2024
Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MAY 16, 2024
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on results of a Phase 1/2 trial. Novartis said it’s met all tender offer conditions to acquire German biotech Morphosys.
STAT
OCTOBER 24, 2024
Among the basic and life-saving medicines for which shortages continue to be problematic are Rho(D) immune globulin, pain and sedation medications, and ADHD pills. So far this year, 95 new shortages were reported, a drop from 156 in 2023, although 50% of active shortages have persisted for two or more years.
Safe Biologics
NOVEMBER 12, 2023
The product is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. It is administered via intravenous infusion.
STAT
FEBRUARY 7, 2025
Bain will acquire a centuries-old drugmaking division currently developing medicines for neurological and immune disorders, among other kinds of conditions, allowing Mitsubishi to focus on its core chemical business. billion, in one of the private equity firm’s largest life science deals.
pharmaphorum
AUGUST 27, 2020
Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. The first is that the development of vaccines is utilising cutting edge technologies.
Expert insights. Personalized for you.
272 
Let's personalize your content